http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 14 Oct 2026 06:39:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C356+at+Wells+Fargo/27183380.html Wells Fargo analyst Derek Archila raised the price target on argenx SE (NASDAQ: ARGX) to $1,356.00 (from $1,355.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Raised+to+%241%2C356+at+Wells+Fargo/27183380.html Wed, 14 Oct 2026 06:39:52 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Lowered+to+%241%2C038+at+Oppenheimer/27174225.html Oppenheimer analyst Leland Gershell lowered the price target on argenx SE (NASDAQ: ARGX) to $1,038.00 (from $1,100.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Lowered+to+%241%2C038+at+Oppenheimer/27174225.html Mon, 12 Oct 2026 08:41:18 -0400 ARGX http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Lowered+to+%24823+at+Baird/27169149.html Baird analyst Colleen Kusy lowered the price target on argenx SE (NASDAQ: ARGX) to $823.00 (from $932.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/argenx+SE+%28ARGX%29+PT+Lowered+to+%24823+at+Baird/27169149.html Fri, 09 Oct 2026 07:21:52 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+argenx+SE+%28ARGX%29/27168937.html <p>H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $1,202.00 price target on argenx SE (NASDAQ: ARGX).</p><p>The analyst commented: "FB102 Phase 2 success strengthens confidence in argenx's newly acquired autoimmune asset. argenx (ARGX; Buy) announced positive topline results from the 126-patient Phase 2 FB102 study in celiac disease, meeting the primary endpoint of change in villus height-to-crypt depth (Vh) ratio at Day 78 (p=0.0176). Supportive effects were also observed across intraepithelial lymphocyte (IEL) density, composite histology (VCIEL), and symptoms, with no new safety signals. Importantly, the results extend the positive Phase 1b findings from a 16-day to an eight-week http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+argenx+SE+%28ARGX%29/27168937.html Fri, 09 Oct 2026 06:42:41 -0400 ARGX http://www.streetinsider.com/General+News/RBC+Capital+keeps+Outperform+rating+on+argenx+with+%241%2C100+target%2C+%27we+are+buyers+into+weakness%27/27164940.html <p>RBC Capital analyst Luca Issi reiterated an Outperform rating and a $1,100.00 price target on argenx SE (NASDAQ: ARGX).</p><p>The reiteration follows a setback in argenx's Sjögren's disease program, which Issi described as "clearly unfortunate," noting that the Phase II trial had shown promising results with 45% CRESS responders versus 11% for placebo. The analyst said the stock decline appeared excessive, noting that Sjögren's contributed $68 to the firm's model while the stock fell nearly twice that amount in pre-market trading.</p><p>Issi also commented on argenx's celiac disease program, noting that a Phase II trial produced a p-value of 0.0176, compared with http://www.streetinsider.com/General+News/RBC+Capital+keeps+Outperform+rating+on+argenx+with+%241%2C100+target%2C+%27we+are+buyers+into+weakness%27/27164940.html Thu, 08 Oct 2026 09:30:01 -0400 ARGX http://www.streetinsider.com/General+News/Truist+Securities+keeps+Buy+rating+on+argenx+after+trial+failure%2C+%27We+believe+the+stock+reaction+is+overdone%27/27164933.html <p>Truist Securities analyst Danielle Brill reiterated a Buy rating and a $1,095.00 price target on argenx SE (NASDAQ: ARGX) after the company discontinued its Phase 3 clinical trial for Sjögren's disease.</p><p>Argenx announced the discontinuation of the trial evaluating efgartigimod following a failed interim futility analysis. Shares of argenx fell approximately 13% following the announcement, closing at $928.44.</p><p>Brill said the discontinuation has no impact on the firm's financial model, noting the Sjögren's program was never incorporated into Truist's valuation. "While the outcome is disappointing, particularly given the sizeable commercial opportunity and potential value inflection from topline data previously expected in 2H27, http://www.streetinsider.com/General+News/Truist+Securities+keeps+Buy+rating+on+argenx+after+trial+failure%2C+%27We+believe+the+stock+reaction+is+overdone%27/27164933.html Thu, 08 Oct 2026 09:28:55 -0400 ARGX http://www.streetinsider.com/General+News/Stifel+keeps+Buy+rating+on+argenx+after+Sjogren%27s+trial+failure/27164928.html <p>Stifel analyst Alex Thompson reiterated a Buy rating and a $1,282.00 price target on argenx SE (NASDAQ: ARGX) after the company's Phase 3 study of efgartigimod in Sjogren's disease was stopped for futility.</p><p>Thompson noted the result was a surprise given positive Phase 2 data from Nipocalimab and argenx's proof-of-concept study, adding that placebo response in Sjogren's disease appears high and unpredictable. The analyst said the outcome removes a potential label expansion opportunity, with data previously expected in the second half of 2027.</p><p>Thompson said the firm remains optimistic about label expansion in myasthenia gravis and a likely approval in immune-mediated necrotizing http://www.streetinsider.com/General+News/Stifel+keeps+Buy+rating+on+argenx+after+Sjogren%27s+trial+failure/27164928.html Thu, 08 Oct 2026 09:28:04 -0400 ARGX http://www.streetinsider.com/Analyst+Comments/Stifel+keeps+Buy+rating+on+argenx+after+Sjogren%27s+trial+failure/27164928.html <p>Stifel analyst Alex Thompson reiterated a Buy rating and a $1,282.00 price target on argenx SE (NASDAQ: ARGX) after the company's Phase 3 study of efgartigimod in Sjogren's disease was stopped for futility.</p><p>Thompson noted the result was a surprise given positive Phase 2 data from Nipocalimab and argenx's proof-of-concept study, adding that placebo response in Sjogren's disease appears high and unpredictable. The analyst said the outcome removes a potential label expansion opportunity, with data previously expected in the second half of 2027.</p><p>Thompson said the firm remains optimistic about label expansion in myasthenia gravis and a likely approval in immune-mediated necrotizing http://www.streetinsider.com/Analyst+Comments/Stifel+keeps+Buy+rating+on+argenx+after+Sjogren%27s+trial+failure/27164928.html Thu, 08 Oct 2026 09:28:04 -0400 ARGX http://www.streetinsider.com/General+News/Citi+keeps+Buy+rating+on+argenx+amid+pipeline+updates%2C+shares+down+11%25/27164926.html <p>Citi analyst Samantha Semenkow reiterated a Buy rating and $1,301.00 price target on argenx SE (NASDAQ: ARGX), following a set of mixed clinical pipeline developments from the company.</p><p>Argenx announced that a Phase 3 pivotal trial for Vyvgart in Sjogren's disease was discontinued following a futility analysis. The company also reported a Phase 2 trial win for FB102, an anti-CD122 treatment, in celiac disease, with argenx confirming advancement of FB102 into a Phase 3 program.</p><p>Semenkow noted that the Sjogren's discontinuation "removes a medium-term expansion opportunity for Vyvgart" and also removes what the analyst described as "arguably an anchor indication as argenx http://www.streetinsider.com/General+News/Citi+keeps+Buy+rating+on+argenx+amid+pipeline+updates%2C+shares+down+11%25/27164926.html Thu, 08 Oct 2026 09:27:07 -0400 ARGX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Oct+08/27163110.html si-local-file:///var/storage/secattach/20261008/27163110.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Oct+08/27163110.html Thu, 08 Oct 2026 06:04:00 -0400 ARGX http://www.streetinsider.com/FDA/argenx+halts+Phase+3+Sj%C3%B6gren%27s+disease+trial+after+futility+finding/27162419.html <p>argenx SE (Euronext & Nasdaq: ARGX) said it will discontinue its Phase 3 UNITY study of efgartigimod subcutaneous (SC) in adults with moderate-to-severe Sjögren's disease after an independent panel recommended stopping the trial.</p> <p>The Independent Data Monitoring Committee (IDMC) conducted an interim analysis and concluded the study was unable to meet its primary endpoint, leading to a recommendation to stop for futility. No new safety signals were identified, and the safety profile was consistent with efgartigimod's established record.</p> <p>The UNITY study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy, safety, and tolerability of efgartigimod SC. Patients were randomized http://www.streetinsider.com/FDA/argenx+halts+Phase+3+Sj%C3%B6gren%27s+disease+trial+after+futility+finding/27162419.html Thu, 08 Oct 2026 01:00:16 -0400 ARGX http://www.streetinsider.com/Press+Releases/argenx+Provides+Update+on+Phase+3+UNITY+Study+of+Efgartigimod+SC+in+Sj%C3%B6gren%26apos%3Bs+Disease/27162416.html <p>October 8, 2026, 7:00 AM CET</p> <p align="justify"><b>Amsterdam, the Netherlands</b> – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren&apos;s disease.</p> <p align="justify">The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded that the UNITY study is unable to meet its primary endpoint. Safety was consistent with efgartigimod&apos;s established profile and no new safety signals http://www.streetinsider.com/Press+Releases/argenx+Provides+Update+on+Phase+3+UNITY+Study+of+Efgartigimod+SC+in+Sj%C3%B6gren%26apos%3Bs+Disease/27162416.html Thu, 08 Oct 2026 01:00:00 -0400 ARGX http://www.streetinsider.com/Globe+Newswire/argenx+Provides+Update+on+Phase+3+UNITY+Study+of+Efgartigimod+SC+in+Sj%C3%B6gren%26apos%3Bs+Disease/27162416.html <p>October 8, 2026, 7:00 AM CET</p> <p align="justify"><b>Amsterdam, the Netherlands</b> – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren&apos;s disease.</p> <p align="justify">The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded that the UNITY study is unable to meet its primary endpoint. Safety was consistent with efgartigimod&apos;s established profile and no new safety signals http://www.streetinsider.com/Globe+Newswire/argenx+Provides+Update+on+Phase+3+UNITY+Study+of+Efgartigimod+SC+in+Sj%C3%B6gren%26apos%3Bs+Disease/27162416.html Thu, 08 Oct 2026 01:00:00 -0400 ARGX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Sep+29/27118148.html si-local-file:///var/storage/secattach/20260929/27118148.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++ARGENX+SE+++++++++++++++++For%3A+Sep+29/27118148.html Tue, 29 Sep 2026 08:38:00 -0400 ARGX http://www.streetinsider.com/Board+Changes/argenx+adds+two+non-executive+directors+to+its+board/27075749.html <p>argenx SE (Nasdaq: ARGX) announced the results of an Extraordinary General Meeting of Shareholders and the appointment of Thomas M. Brakel and Khurem Farooq as non-executive directors to its Board of Directors, according to a company statement dated September 17, 2026.</p><p>Tim Van Hauwermeiren, Chairperson of the Board of argenx, commented on the appointments: "We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. As we look ahead to Vision 2030 and beyond, we are building a company, and a board, with the strength and perspective to sustain and grow http://www.streetinsider.com/Board+Changes/argenx+adds+two+non-executive+directors+to+its+board/27075749.html Thu, 17 Sep 2026 16:03:24 -0400 ARGX http://www.streetinsider.com/Corporate+News/argenx+adds+two+non-executive+directors+to+its+board/27075749.html <p>argenx SE (Nasdaq: ARGX) announced the results of an Extraordinary General Meeting of Shareholders and the appointment of Thomas M. Brakel and Khurem Farooq as non-executive directors to its Board of Directors, according to a company statement dated September 17, 2026.</p><p>Tim Van Hauwermeiren, Chairperson of the Board of argenx, commented on the appointments: "We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. As we look ahead to Vision 2030 and beyond, we are building a company, and a board, with the strength and perspective to sustain and grow http://www.streetinsider.com/Corporate+News/argenx+adds+two+non-executive+directors+to+its+board/27075749.html Thu, 17 Sep 2026 16:03:24 -0400 ARGX http://www.streetinsider.com/Press+Releases/argenx+announces+results+of+Extraordinary+General+Meeting+of+Shareholders+and+appointment+of+Thomas+M.+Brakel+and+Khurem+Farooq+as+Non-Executive+Directors/27075740.html <p align="justify"><b>September 17, 2026</b><b> – 22:01PM CET</b></p> <p align="justify"><b>Amsterdam, the Netherlands</b> – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company’s Board of Directors.</p> <p align="justify"><i>“We welcome Tom and Khurem to the Board and look forward to learning from their combined years of leadership and expertise. Our focus at argenx today remains as ever before, on our scientific innovation mission, delivering value for shareholders, and always deepening the impact we http://www.streetinsider.com/Press+Releases/argenx+announces+results+of+Extraordinary+General+Meeting+of+Shareholders+and+appointment+of+Thomas+M.+Brakel+and+Khurem+Farooq+as+Non-Executive+Directors/27075740.html Thu, 17 Sep 2026 16:02:00 -0400 ARGX